BioAtla, Inc. Common Stock
BCAB
BCAB: BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise Mecbotamab vedotin, Ozuriftabmab vedotin, BA3071, and Bispecific antibody programs.
moreShow BCAB Financials
Recent trades of BCAB by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by BCAB's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Mirac proteins Aug. 08, 2023
-
Patent Title: Methods of protein evolution May. 02, 2023
-
Patent Title: Conditionally active chimeric antigen receptors for modified t-cells Feb. 21, 2023
-
Patent Title: Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof Jan. 03, 2023
-
Patent Title: Conditionally active polypeptides Oct. 18, 2022
-
Patent Title: Comprehensive monoclonal antibody generation Jul. 26, 2022
-
Patent Title: Express humanization of antibodies Jul. 26, 2022
-
Patent Title: Proteins targeting orthologs Apr. 05, 2022
-
Patent Title: Conditionally active polypeptides and methods of generating them Mar. 22, 2022
-
Patent Title: Conditionally active biological proteins Feb. 22, 2022
-
Patent Title: Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof Feb. 22, 2022
-
Patent Title: Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof Oct. 19, 2021
-
Patent Title: Conditionally active chimeric antigen receptors for modified t-cells Sep. 07, 2021
-
Patent Title: Modified antibody regions and uses thereof Mar. 23, 2021
-
Patent Title: Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts Feb. 16, 2021
-
Patent Title: Methods of protein evolution Nov. 10, 2020
-
Patent Title: Diagnostics using conditionally active antibodies Jun. 30, 2020
-
Patent Title: Multi-specific monoclonal antibodies Jun. 30, 2020
-
Patent Title: Comprehensive monoclonal antibody generation Jun. 02, 2020
-
Patent Title: Express humanization of antibodies Feb. 18, 2020
-
Patent Title: Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts Dec. 24, 2019
-
Patent Title: Conditionally active biological proteins Jun. 25, 2019
-
Patent Title: Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts Oct. 23, 2018
-
Patent Title: Methods of protein evolution Oct. 23, 2018
-
Patent Title: Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts Aug. 14, 2018
-
Patent Title: Mirac proteins Jun. 12, 2018
-
Patent Title: Mirac proteins May. 29, 2018
-
Patent Title: Multi-specific monoclonal antibodies May. 15, 2018
-
Patent Title: Anti-cd22 antibodies Jan. 02, 2018
-
Patent Title: Mirac proteins May. 02, 2017
-
Patent Title: Mirac proteins May. 02, 2017
-
Patent Title: Mirac proteins Oct. 11, 2016
-
Patent Title: Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts Oct. 14, 2014
-
Patent Title: Mirac proteins Apr. 29, 2014
Federal grants, loans, and purchases
Followers on BCAB's company Twitter account
Number of mentions of BCAB in WallStreetBets Daily Discussion
Recent insights relating to BCAB
Recent picks made for BCAB stock on CNBC
ETFs with the largest estimated holdings in BCAB
Flights by private jets registered to BCAB